Table 1.
League table of pain freedom at 2 h
| DFN-02 | 2.67 (0.98,7.30) | ||||||||||
| 0.70 (0.19,2.60) | Ket | 1.19 (0.50,2.86) | 3.34 (1.25,8.87) | ||||||||
| 0.88 (0.27,2.91) | 1.25 (0.44,3.54) | AVP-825 | 3.03(1.63,5.62) | ||||||||
| 1.35 (0.31,5.88) | 1.91 (0.49,7.40) | 1.52 (0.44,5.28) | ROX-828 | 1.99 (0.66,5.83) | |||||||
| 1.41 (0.45,4.36) | 2.00 (0.83,4.83) | 1.59 (0.71,3.56) | 1.04 (0.32,3.41) | Suma10mg | 0.52 (0.34,0.79) | 1.82 (1.19,3.14) | |||||
| 0.77 (0.26,2.32) | 1.10 (0.49,2.45) | 0.87 (0.41,1.87) | 0.57 (0.18,1.81) | 0.55 (0.36,0.83) | Suma20mg | 3.48 (2.26,5.33) | |||||
| 0.86 (0.28,2.67) | 1.23 (0.47,3.22) | 0.98 (0.44,2.17) | 0.64 (0.20,2.09) | 0.61 (0.30,1.24) | 1.12 (0.58,2.16) | Zol2.5 mg | *0.59 (0.37,0.94) | 3.06 (1.74,5.59) | |||
| 0.57 (0.20,1.65) | 0.82 (0.34,1.97) | 0.65 (0.32,1.30) | 0.43 (0.14,1.30) | 0.41 (0.23,0.74) | 0.74 (0.44,1.26) | a0.66 (0.42,1.05) | Zol5mg | 4.66 (3.43,6.35) | |||
| 1.59 (0.54,4.65) | 2.26 (0.92,5.56) | 1.80 (0.87,3.71) | 1.18 (0.38,3.65) | 1.13 (0.61,2.09) | 2.06 (1.18,3.60) | 1.84 (1.01,3.40) | 2.77 (1.73,4.44) | Zave | 1.68 (1.18,2.41) | ||
| 0.73 (0.23,2.29) | 1.03 (0.39,2.77) | 0.82 (0.36,1.88) | 0.54 (0.16,1.79) | b0.52 (0.25,1.08) | 0.94 (0.47,1.87) | 0.84 (0.41,1.74) | 1.27 (0.69,2.34) | 0.46 (0.24,0.87) | MAP0004 | 3.67 (2.18,3.20) | |
| 0.73 (0.17,3.22) | 1.04 (0.27,4.06) | 0.83 (0.24,2.90) | 0.54 (0.12,2.49) | 0.52 (0.16,1.72) | 0.95 (0.29,3.04) | 0.84 (0.26,2.79) | 1.27 (0.41,3.93) | 0.46 (0.15,1.44) | 1.00 (0.30,3.37) | Buto | 3.67(1.25,10.7) |
| b2.68 (0.97,7.38) | 3.81 (1.67,8.70) | 3.03 (1.62,5.69) | 1.99 (0.68,5.81) | 1.91 (1.15,3.15) | 3.48 (2.27,5.33) | 3.10 (1.89,5.10) | 4.67 (3.43,6.34) | 1.68 (1.18,2.41) | 3.69 (2.15,6.31) | 3.67 (1.24,10.87) | Placebo |
Pairwise (upper-right portion) and network (lower-left portion) meta-analysis results are presented as estimated effect sizes for pain freedom at 2 h. For the result, outcomes are expressed as odds ratios (OR) with 95% credible interval (CI) (OR of > 1 indicated that the treatment specified in the row got more improvement than that specified in the column), 0 < OR < 1, the opposite. For the network meta-analysis, OR of > 1 indicated that the treatment specified in the column got better improvement than that specified in the row, 0 < OR < 1, the opposite. 95% CI that did not contain one was considered to have a statistical difference
Bold results indicated statistical significance. Marked with aindicated a significant difference between direct and mixed comparisons. bindicated a significant difference between the basic model and sensitivity analysis
DFN-02, sumatriptan nose spray 10 mg with a permeation enhancer; Ket, ketorolac nose spray 31.5 mg; Suma10mg, sumatriptan nose spray 10 mg; Suma20mg, sumatriptan nose spray 20 mg; Zol2.5 mg, zolmitriptan nose spray 2.5 mg; Zol5mg, zolmitriptan nose spray 5 mg; Zave, zavegepant nose spray 10 mg; Buto, butorphanol nose spray 1 mg; AVP-825, a drug-device combination of 22 mg sumatriptan powder; MAP0004, a dihydroergotamine inhaler; ROX-828, ketorolac 31.5 mg with 6% of lidocaine; DHE, dihydroergotamine nose spray 2 mg